Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457200 | 0.90 | TRPA1 (0.46) | POLBTRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL5126434 | 0.88 | TRPV1 (0.52) | POLBTRPA1TRPV1GPR119 | |
| SCHEMBL5116605 | 0.88 | TRPA1 (0.42) | POLBTRPA1TRPV1GPR119 | |
| SCHEMBL5115851 | 0.85 | TRPA1 (0.46) | TRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL2207487 | 0.85 | TRPA1 (0.47) | TRPA1TRPV1KCNH2TRPM8CNR2 | |
| SCHEMBL2208267 | 0.85 | TRPA1 (0.47) | TRPA1TRPV1KCNH2TRPM8CNR2 | |
| SCHEMBL2207492 | 0.85 | TRPA1 (0.47) | TRPA1TRPV1KCNH2TRPM8CNR2 | |
| SCHEMBL15397892 | 0.84 | TRPA1 (0.47) | TRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL2421627 | 0.83 | TRPA1 (0.68) | POLBTRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL15397894 | 0.83 | TRPA1 (0.46) | TRPA1TRPV1KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292625-A1 | Substituted spiro compounds and their use for producing pain-relief medicaments | Grünenthal GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | POLB 3854/4885TRPA1 720/4885TRPV1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.